Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Existing hepatocellular carcinoma (HCC) prediction models are derived mainly from pretreatment or early on-treatment parameters. We reassessed the dynamic changes in the performance of 17 HCC models in patients with chronic hepatitis B (CHB) during long-term antiviral therapy (AVT). Methods: Among 987 CHB patients administered long-term entecavir therapy, 660 patients had 8 years of follow-up data. Model scores were calculated using on-treatment values at 2.5, 3, 3.5, 4, 4.5, and 5 years of AVT to predict threeyear HCC occurrence. Model performance was assessed with the area under the receiver operating curve (AUROC). The original model cutoffs to distinguish different levels of HCC risk were evaluated by the log-rank test. Results: The AUROCs of the 17 HCC models varied from 0.51 to 0.78 when using on-treatment scores from years 2.5 to 5. Models with a cirrhosis variable showed numerically higher AUROCs (pooled at 0.65–0.73 for treated, untreated, or mixed treatment models) than models without (treated or mixed models: 0.61–0.68; untreated models: 0.51–0.59). Stratification into low, intermediate, and high-risk levels using the original cutoff values could no longer reflect the true HCC incidence using scores after 3.5 years of AVT for models without cirrhosis and after 4 years of AVT for models with cirrhosis. Conclusions: The performance of existing HCC prediction models, especially models without the cirrhosis variable, decreased in CHB patients on long-term AVT. The optimization of existing models or the development of novel models for better HCC prediction during long-term AVT is warranted.
Abstract
Background/Aims: Existing hepatocellular carcinoma (HCC) prediction models are derived mainly from pretreatment or early on-treatment parameters. We reassessed the dynamic changes in the performance of 17 HCC models in patients with chronic hepatitis B (CHB) during long-term antiviral therapy (AVT). Methods: Among 987 CHB patients administered long-term entecavir therapy, 660 patients had 8 years of follow-up data. Model scores were calculated using on-treatment values at 2.5, 3, 3.5, 4, 4.5, and 5 years of AVT to predict threeyear HCC occurrence. Model performance was assessed with the area under the receiver operating curve (AUROC). The original model cutoffs to distinguish different levels of HCC risk were evaluated by the log-rank test. Results: The AUROCs of the 17 HCC models varied from 0.51 to 0.78 when using on-treatment scores from years 2.5 to 5. Models with a cirrhosis variable showed numerically higher AUROCs (pooled at 0.65–0.73 for treated, untreated, or mixed treatment models) than models without (treated or mixed models: 0.61–0.68; untreated models: 0.51–0.59). Stratification into low, intermediate, and high-risk levels using the original cutoff values could no longer reflect the true HCC incidence using scores after 3.5 years of AVT for models without cirrhosis and after 4 years of AVT for models with cirrhosis. Conclusions: The performance of existing HCC prediction models, especially models without the cirrhosis variable, decreased in CHB patients on long-term AVT. The optimization of existing models or the development of novel models for better HCC prediction during long-term AVT is warranted.
참고문헌 (37)
- Yip TC, "HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viralsuppression with nucleos(t)ide analogues", J Hepatol, 70, pp.361~370 (2019)
- Su TH, "Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients", Liver Int, 36, pp.1755~1764 (2016)
- Wu S, "Comparative performance of 14 HCC prediction models in CHB : A dynamic validation at serial on-treatment timepoints", Am J Gastroenterol, 117, pp.1444~1453 (2022)
- Chan HL, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.185~195 (2016)
- Wong GL, "Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy", World J Gastroenterol, 19, pp.6515~6522 (2013)
- Wu S, "On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis", Liver Int, 38, pp.1045~1054 (2018)
- Wu X, "Prediction of liver-related events in patients with compensated HBV-induced cirrhosisreceiving antiviral therapy", Hepatol Int, 15, pp.82~92 (2021)
- Wu S, "Hepatocellular carcinoma prediction models in chronic hepatitis B : A systematic review of 14 models and external validation", Clin Gastroenterol Hepatol, 19, pp.2499~2513 (2021)
- Fan R, "aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis", J Hepatol, 73, pp.1368~1378 (2020)
- Papatheodoridis GV, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B", J Hepatol, 72, pp.1088~1096 (2020)
- Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACH-B) : development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
- Yang HI, "Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection", J Clin Oncol, 28, pp.2437~2444 (2010)
- Yuen MF, "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B", J Hepatol, 50, pp.80~88 (2009)
- Lee HW, "Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy", Am J Gastroenterol, 109, pp.1241~1249 (2014)
- Wong GL, "Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B", J Hepatol, 60, pp.339~345 (2014)
- Kim JH, "Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy", J Hepatol, 69, pp.1066~1073 (2018)
- Papatheodoridis G, "PAGE-B predictsthe risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy", J Hepatol, 64, pp.800~806 (2016)
- Yu JH, "Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir", tenofovir, 2019, pp.31, 865~872
- Hsu YC, "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B", J Hepatol, 69, pp.278~285 (2018)
- Yang HI, "Real-World effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy", J Infect Dis, 221, pp.389~399 (2020)
- Wong VW, "Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers", J Clin Oncol, 28, pp.1660~1665 (2010)
- Poh Z, "Realworld risk score for hepatocellular carcinoma(RWS-HCC) : a clinically practical risk predictor for HCC in chronic hepatitis B", Gut, 65, pp.887~888 (2016)
- Alba AC, "Discrimination and calibration of clinical prediction models : Users’ guides to the medical literature", JAMA, 318, pp.1377~1384 (2017)
- Benjamini Y, "Controlling the false discovery rate : a practical and powerful approach to multiple hypothesis testing", J R Stat Soc Series B Stat Methodol, 57, pp.289~300 (1995)
- Papatheodoridis GV, "The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B", Hepatology, 66, pp.1444~1453 (2017)
- Jung Hwan Yu, "The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection", Clinical and Molecular Hepatology, 28(3), pp.351~361 (2022), 대한간학회[DOI]
- Croagh CM, "Natural history of chronic hepatitis B : phases in a complex relationship", World J Gastroenterol, 20, pp.10395~10404 (2014)
- Abu-Amara M, "The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection", Gut, 65, pp.1347~1358 (2016)
- Marcellin P, "Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B", Liver Int, 29, pp.242~247 (2009)
- Karasu Z, "Liver fibrosis is associated with decreased peripheral platelet count in patientswith chronic hepatitis B and C", Dig Dis Sci, 52, pp.1535~1539 (2007)
- Hsu YC, "Application of risk scores for hepatocellular carcinoma in patients with chronic hepatitis B : Current status and future perspective", Semin Liver Dis, 41, pp.285~297 (2021)
- Bruix J, "Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
- Lee JS, "External validation of the FSAC model using on-therapy changes in noninvasive fibrosis markers in patients with chronic hepatitis B: A multicenterstudy", Cancers(Basel), 14, pp.711~ (2022)
- Yip TC, "Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B", J Hepatol, 72, pp.847~854 (2020)
- Papatheodoridis GV, "Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir", J Hepatol, 62, pp.363~370 (2015)
- Lee JS, "Suboptimal performance of hepatocellular carcinoma prediction models in patients with hepatitis B virus-related cirrhosis", Diagnostics(Basel), 13, pp.3~ (2022)
- Sang Jin Kim, "Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review", Clinical and Molecular Hepatology, 28(4), pp.739~753 (2022), 대한간학회